Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Maria Matera and Mario Cazzola.
Maria Matera
Connection Strength
30.994
Mario Cazzola
  1. Use of Thiols in the Treatment of COVID-19: Current Evidence. Lung. 2021 08; 199(4):335-343.
    View in: PubMed
    Score: 0.964
  2. Controversy surrounding the Sputnik V vaccine. Respir Med. 2021 10; 187:106569.
    View in: PubMed
    Score: 0.961
  3. Management of COPD patients during COVID: difficulties and experiences. Expert Rev Respir Med. 2021 08; 15(8):1025-1033.
    View in: PubMed
    Score: 0.946
  4. Disputes over the production and dissemination of misinformation in the time of COVID-19. Respir Med. 2021 06; 182:106380.
    View in: PubMed
    Score: 0.937
  5. Guidance on nebulization during the current COVID-19 pandemic. Respir Med. 2021 01; 176:106236.
    View in: PubMed
    Score: 0.914
  6. Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review. Respir Med. 2020 09; 171:106114.
    View in: PubMed
    Score: 0.896
  7. Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. Expert Opin Investig Drugs. 2019 Oct; 28(10):827-833.
    View in: PubMed
    Score: 0.840
  8. Pharmacological treatment and current controversies in COPD. F1000Res. 2019; 8.
    View in: PubMed
    Score: 0.840
  9. Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. Trends Pharmacol Sci. 2019 07; 40(7):452-463.
    View in: PubMed
    Score: 0.825
  10. Bronchodilators in subjects with asthma-related comorbidities. Respir Med. 2019 05; 151:43-48.
    View in: PubMed
    Score: 0.816
  11. Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease. Pharm Pat Anal. 2018 Nov; 7(6):249-257.
    View in: PubMed
    Score: 0.805
  12. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J. 2018 12; 52(6).
    View in: PubMed
    Score: 0.799
  13. Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. Expert Opin Pharmacother. 2018 Dec; 19(18):2043-2053.
    View in: PubMed
    Score: 0.792
  14. Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Metab Toxicol. 2018 Oct; 14(10):1101-1111.
    View in: PubMed
    Score: 0.790
  15. POINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? Yes. Chest. 2018 10; 154(4):746-748.
    View in: PubMed
    Score: 0.788
  16. Rebuttal From Drs Cazzola and Matera. Chest. 2018 10; 154(4):751-752.
    View in: PubMed
    Score: 0.788
  17. Combining Dual Bronchodilation and ß-Blockade in Patients With an Overlap Between COPD and Cardiovascular Diseases. Chest. 2018 06; 153(6):1289-1291.
    View in: PubMed
    Score: 0.770
  18. Editorial overview: Respiratory: Pulmonary pharmacology - It is time for a breath of fresh air. Curr Opin Pharmacol. 2018 06; 40:iv-viii.
    View in: PubMed
    Score: 0.770
  19. Impact of doxofylline in COPD: A pairwise meta-analysis. Pulm Pharmacol Ther. 2018 08; 51:1-9.
    View in: PubMed
    Score: 0.765
  20. A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. Expert Opin Drug Saf. 2018 05; 17(5):509-517.
    View in: PubMed
    Score: 0.758
  21. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. Expert Opin Drug Metab Toxicol. 2018 Feb; 14(2):239-245.
    View in: PubMed
    Score: 0.748
  22. Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. Pulm Pharmacol Ther. 2018 02; 48:185-194.
    View in: PubMed
    Score: 0.745
  23. Doxofylline is not just another theophylline! Int J Chron Obstruct Pulmon Dis. 2017; 12:3487-3493.
    View in: PubMed
    Score: 0.745
  24. An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? Expert Rev Respir Med. 2018 01; 12(1):43-54.
    View in: PubMed
    Score: 0.740
  25. Pharmacogenetic and pharmacogenomic considerations of asthma treatment. Expert Opin Drug Metab Toxicol. 2017 Nov; 13(11):1159-1167.
    View in: PubMed
    Score: 0.739
  26. Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus. Trends Pharmacol Sci. 2017 10; 38(10):940-951.
    View in: PubMed
    Score: 0.728
  27. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. COPD. 2017 Oct; 14(5):552-563.
    View in: PubMed
    Score: 0.727
  28. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma. Expert Opin Drug Metab Toxicol. 2017 Sep; 13(9):1007-1013.
    View in: PubMed
    Score: 0.726
  29. An update on the pharmacotherapeutic management of lower respiratory tract infections. Expert Opin Pharmacother. 2017 Jul; 18(10):973-988.
    View in: PubMed
    Score: 0.717
  30. Bronchodilator therapy for chronic cough. Pulm Pharmacol Ther. 2017 Dec; 47:88-92.
    View in: PubMed
    Score: 0.717
  31. Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. Drugs. 2017 May; 77(7):721-732.
    View in: PubMed
    Score: 0.715
  32. Role of muscarinic antagonists in asthma therapy. Expert Rev Respir Med. 2017 03; 11(3):239-253.
    View in: PubMed
    Score: 0.704
  33. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. Respir Res. 2017 01 24; 18(1):26.
    View in: PubMed
    Score: 0.702
  34. Tiotropium formulations and safety: a network meta-analysis. Ther Adv Drug Saf. 2017 Jan; 8(1):17-30.
    View in: PubMed
    Score: 0.684
  35. ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD? Drugs. 2007; 67(4):503-15.
    View in: PubMed
    Score: 0.349
  36. Bronchodilator Response as a Possible Predictor of Lung Function Improvement After Pulmonary Rehabilitation in Post-COVID-19 Patients. Arch Bronconeumol (Engl Ed). 2021 Jun 18.
    View in: PubMed
    Score: 0.238
  37. Preexisting cardiorespiratory comorbidity does not preclude the success of multidisciplinary rehabilitation in post-COVID-19 patients. Respir Med. 2021 08; 184:106470.
    View in: PubMed
    Score: 0.236
  38. Bronchodilator reversibility testing in post-COVID-19 patients undergoing pulmonary rehabilitation. Respir Med. 2021 06; 182:106401.
    View in: PubMed
    Score: 0.235
  39. A potential role of triple therapy for asthma patients. Expert Rev Respir Med. 2019 11; 13(11):1079-1085.
    View in: PubMed
    Score: 0.210
  40. Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease. Expert Rev Respir Med. 2018 08; 12(8):693-708.
    View in: PubMed
    Score: 0.194
  41. Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells. Eur J Pharmacol. 2018 Aug 05; 832:114-119.
    View in: PubMed
    Score: 0.192
  42. N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. Biomed Pharmacother. 2018 Jul; 103:1-8.
    View in: PubMed
    Score: 0.191
  43. Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy. Curr Opin Pharmacol. 2018 06; 40:95-103.
    View in: PubMed
    Score: 0.190
  44. How does race/ethnicity influence pharmacological response to asthma therapies? Expert Opin Drug Metab Toxicol. 2018 Apr; 14(4):435-446.
    View in: PubMed
    Score: 0.190
  45. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab. Expert Opin Drug Saf. 2018 Apr; 17(4):429-435.
    View in: PubMed
    Score: 0.190
  46. Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how. Expert Rev Respir Med. 2018 04; 12(4):261-264.
    View in: PubMed
    Score: 0.189
  47. Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. Pulm Pharmacol Ther. 2018 04; 49:20-26.
    View in: PubMed
    Score: 0.187
  48. Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi. COPD. 2017 Oct; 14(5):526-532.
    View in: PubMed
    Score: 0.182
  49. Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. Eur J Pharmacol. 2017 Oct 05; 812:147-154.
    View in: PubMed
    Score: 0.181
  50. Adherence to COPD treatment: Myth and reality. Respir Med. 2017 08; 129:117-123.
    View in: PubMed
    Score: 0.180
  51. Optimizing drug delivery in COPD: The role of inhaler devices. Respir Med. 2017 03; 124:6-14.
    View in: PubMed
    Score: 0.175
  52. LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. Eur Respir Rev. 2017 Jan; 26(143).
    View in: PubMed
    Score: 0.175
  53. Comments on "Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations" by D'Amato et al. Multidiscip Respir Med. 2021 Jan 15; 16(1):757.
    View in: PubMed
    Score: 0.058
  54. ACE2: The Major Cell Entry Receptor for SARS-CoV-2. Lung. 2020 12; 198(6):867-877.
    View in: PubMed
    Score: 0.057
  55. Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter? Respir Med. 2020 07; 168:105996.
    View in: PubMed
    Score: 0.055
  56. Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2019 04; 20(6):737-750.
    View in: PubMed
    Score: 0.050
  57. The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. Expert Opin Drug Saf. 2018 06; 17(6):589-596.
    View in: PubMed
    Score: 0.048
  58. Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways. Respir Res. 2018 04 12; 19(1):65.
    View in: PubMed
    Score: 0.048
  59. Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. Pulm Pharmacol Ther. 2018 06; 50:28-37.
    View in: PubMed
    Score: 0.048
  60. Withdrawal of inhaled corticosteroids in COPD: A meta-analysis. Pulm Pharmacol Ther. 2017 08; 45:148-158.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.